PALISADE CAPITAL MANAGEMENT, LP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$1,138,650
+23.4%
1,500,0000.0%0.03%
+28.0%
Q2 2023$922,573
-3.5%
1,500,0000.0%0.02%
-3.8%
Q1 2023$956,261
-17.2%
1,500,000
-50.0%
0.03%
-16.1%
Q4 2022$1,155,000
-13.2%
3,000,0000.0%0.03%
-18.4%
Q3 2022$1,331,000
+5.4%
3,000,0000.0%0.04%
+11.8%
Q2 2022$1,263,000
-11.6%
3,000,0000.0%0.03%
+3.0%
Q1 2022$1,429,0003,000,0000.03%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
INHERENT GROUP, LP 39,500,000$15,386,3964.59%
Athyrium Capital Management, LP 20,000,000$7,753,9003.26%
Diameter Capital Partners LP 43,287,000$16,786,9152.61%
Affinity Asset Advisors, LLC 10,000,000$3,895,2901.53%
DeepCurrents Investment Group LLC 39,355,000$14,590,7460.57%
BRAIDWELL LP 42,294,000$16,151,0210.54%
Context Capital Management, LLC 16,458$6,2850.46%
Aequim Alternative Investments LP 31,000,000$11,838,1250.32%
ARISTEIA CAPITAL, L.L.C. 40,816,000$15,586,6100.31%
ABSOLUTE INVESTMENT ADVISERS, LLC 5,000,000$1,875,0000.28%
View complete list of BRIDGEBIO PHARMA INC shareholders